Key result
Lp(a) rises during ACS by ~13 mg/dL, driven independently by acute CRP levels.
Why the study?
Although a single lifetime measurement of genetically determined Lp(a) has traditionally been considered sufficient, emerging evidence suggests Lp(a) may fluctuate during the acute phase of ACS. The clinical determinants of acute-phase Lp(a) changes and their temporal pattern following ACS needed to be identified and characterized.
Observational (n=84)
No
Lp(a) exhibits a transient, non-linear increase during the acute phase of ACS driven by inflammation (CRP), indicating that early post-ACS Lp(a) measurements may not reflect steady-state levels.
Background Lipoprotein(a) [Lp(a)] is an independent risk factor for atherosclerotic cardiovascular disease. Because circulating Lp(a) levels are largely genetically determined by the LPA gene, a single lifetime measurement has traditionally been considered sufficient. However, emerging evidence suggests that Lp(a) may fluctuate during the acute phase of acute coronary syndrome (ACS), with a possible peak around two weeks after onset. We aimed to identify clinical determinants of acute-phase Lp(a) changes and characterize its temporal pattern following ACS. Methods This single-center retrospective study included consecutive ACS patients undergoing percutaneous coronary intervention between January 2023 and January 2026. All received intensive statin therapy and had at least two Lp(a) measurements: at admission and within 30 days. Baseline Lp(a) was defined as the value within 72 hours of admission. ΔLp(a) was calculated as follow-up minus baseline Lp(a).Correlations between ΔLp(a) within 14 days and peak creatine kinase-MB (CK-MB), peak C-reactive protein (CRP), peak aspartate aminotransferase (AST), estimated glomerular filtration rate (eGFR), and baseline Lp(a) were assessed. Multivariable linear regression identified independent determinants. Linear and quadratic regression models were applied to evaluate the overall time-course pattern. Results Eighty-four patients were analyzed (mean age 69.4 years; 21.4% female). Baseline Lp(a) was 20.8 ± 19.0 mg/dL. Mean ΔLp(a) was 13.3 ± 14.1 mg/dL, with a maximum increase of 72 mg/dL at 12 days.ΔLp(a) within 14 days correlated with baseline Lp(a) (r = 0.42, p < 0.001) and CRP (r = 0.27, p = 0.016), but not with CK-MB or AST. In multivariable analysis adjusting for age, sex, timing, CRP, and baseline Lp(a), CRP (β = 0.64, p = 0.001) and baseline Lp(a) (β = 0.33, p < 0.001) remained independently associated with ΔLp(a). Quadratic regression demonstrated a significant non-linear trajectory (p for non-linearity = 0.012). Conclusions Lp(a) shows a transient, non-linear increase during the acute phase of ACS associated with inflammatory response. Early post-ACS Lp(a) measurements may not reflect steady-state levels and should be interpreted cautiously.
No takes yet. Share an insight, caveat, or question.
Fujioka et al. (2026) conducted an observational in Acute coronary syndrome (n=84). Acute phase of acute coronary syndrome and clinical determinants (CRP, baseline Lp(a)) vs. Baseline Lp(a) within 72 hours of admission was evaluated on Acute-phase change in lipoprotein(a) [ΔLp(a)] (β 0.64 for CRP; β 0.33 for baseline Lp(a), p=0.001). Lipoprotein(a) increased non-linearly during acute coronary syndrome (mean ΔLp(a) 13.3 mg/dL, p=0.012), driven independently by C-reactive protein (β=0.64, p=0.001) and baseline Lp(a) (β=0.33, p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: